Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabergoline in Non-functioning Pituitary Adenomas
NCT02288962Phase 3Active, not recruiting
- Sponsor
- St. Olavs University Hospital
- Start
- Nov 2014
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of cabergoline in non-functioning pituitary adenoma (NFPA), sponsored by St. Olavs University Hospital. Started Nov 2014; status: active, not recruiting.
02
Drugs
cabergoline
03
Conditions
non-functioning pituitary adenoma (NFPA)
Beyond the preview
Go deeper on NCT02288962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02288962.